CA1050426A - Process for the production of pharmaceutical composition of insulin for rectal use - Google Patents

Process for the production of pharmaceutical composition of insulin for rectal use

Info

Publication number
CA1050426A
CA1050426A CA261,342A CA261342A CA1050426A CA 1050426 A CA1050426 A CA 1050426A CA 261342 A CA261342 A CA 261342A CA 1050426 A CA1050426 A CA 1050426A
Authority
CA
Canada
Prior art keywords
insulin
ether
polyoxyethylene
poe
surface active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA261,342A
Other languages
English (en)
French (fr)
Inventor
Hiroitsu Kawada
Hiroo Maeno
Shigeo Kawamura
Isao Ohata
Kunihide Ichikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP50116028A external-priority patent/JPS5241210A/ja
Priority claimed from JP50117810A external-priority patent/JPS5244222A/ja
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of CA1050426A publication Critical patent/CA1050426A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA261,342A 1975-09-26 1976-09-16 Process for the production of pharmaceutical composition of insulin for rectal use Expired CA1050426A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP50116028A JPS5241210A (en) 1975-09-26 1975-09-26 Method of making insulin preparations for rectal administration
JP50117810A JPS5244222A (en) 1975-09-30 1975-09-30 Method of making insulin preparations for rectal application

Publications (1)

Publication Number Publication Date
CA1050426A true CA1050426A (en) 1979-03-13

Family

ID=26454417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA261,342A Expired CA1050426A (en) 1975-09-26 1976-09-16 Process for the production of pharmaceutical composition of insulin for rectal use

Country Status (8)

Country Link
AT (1) AT344327B (OSRAM)
CA (1) CA1050426A (OSRAM)
DE (1) DE2641819A1 (OSRAM)
DK (1) DK431876A (OSRAM)
FR (1) FR2325386A1 (OSRAM)
GB (1) GB1563311A (OSRAM)
NO (1) NO146044C (OSRAM)
SE (1) SE7610595L (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6042766B2 (ja) * 1978-12-09 1985-09-25 日本化薬株式会社 基剤
EP0018609B1 (de) * 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
DE2917535C2 (de) * 1979-04-30 1986-10-30 Hoechst Ag, 6230 Frankfurt Gegen Denaturierung beständige Insulinlösungen
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3171774D1 (en) 1980-03-31 1985-09-19 Teijin Ltd Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
SU1011126A1 (ru) * 1981-07-14 1983-04-15 Всесоюзный научно-исследовательский и испытательный институт медицинской техники Средство дл лечени сахарного диабета
JPS58501125A (ja) * 1981-07-17 1983-07-14 ノルデイスク・インスリンラボラトリウム 安定な水性治療性インシユリン製剤及びその製造方法
US4582820A (en) * 1982-12-23 1986-04-15 Research Corporation Orally administered biologically active peptides and proteins
DE3443877A1 (de) * 1984-06-09 1985-12-12 Hoechst Ag Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung
GB8417895D0 (en) * 1984-07-13 1984-08-15 Marples B A Pharmaceutical anti-fungal composition
JPH0651637B2 (ja) 1985-03-28 1994-07-06 エーザイ株式会社 ペプタイドの吸着防止組成物
US4760059A (en) * 1985-08-05 1988-07-26 Hoffmann-La Roche Inc. Rectal dosage form
EP1401406A2 (en) * 2001-07-02 2004-03-31 Merrion Research I Limited Delivery of a bioactive material
JP4646669B2 (ja) 2005-03-30 2011-03-09 キヤノン株式会社 吐出用液体、吐出方法、液滴化方法、カートリッジ及び吐出装置
JP5605760B2 (ja) * 2010-01-18 2014-10-15 セイコーエプソン株式会社 吐出用液体、生体試料の吐出方法、及び化合物

Also Published As

Publication number Publication date
ATA713376A (de) 1977-11-15
NO146044C (no) 1982-08-04
NO763296L (OSRAM) 1977-03-29
FR2325386A1 (fr) 1977-04-22
DK431876A (da) 1977-03-27
AT344327B (de) 1978-07-10
SE7610595L (sv) 1977-03-27
GB1563311A (en) 1980-03-26
DE2641819A1 (de) 1977-04-07
FR2325386B1 (OSRAM) 1979-01-12
NO146044B (no) 1982-04-13

Similar Documents

Publication Publication Date Title
CA1050426A (en) Process for the production of pharmaceutical composition of insulin for rectal use
US5869090A (en) Transdermal delivery of dehydroepiandrosterone
US5521166A (en) Antiprogestin cyclophasic hormonal regimen
CA2174327C (en) Combination of progesterone antagonists and anti-oestrogens with partial agonistic action for use in hormone-replacement therapy for peri- and post-menopausal women
IE65864B1 (en) Treatment of postmenopausal disorders
ZORRILLA et al. Severe endogenous hypertriglyceridemia during treatment with estrogen and oral contraceptives
AU3412300A (en) Low dose estrogen interrupted hormone replacement therapy
US5709878A (en) Transdermal delivery of dehydroepiandrosterone
Cheymol et al. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects
DE102005034498A1 (de) Orale Kontrazeption mit Trimegeston
MXPA06013418A (es) Composiciones y metodos para el tratamiento del trastorno disforico premenstrual.
US12318396B1 (en) Oral (17-β)-3-oxoandrost-4-en-17-yl tridecanoate therapy
AP1171A (en) Hormonal composition consisting of an oestrogen compound and of a progestational compound.
Zondek Hypophyseal tumors induced by estrogenic hormone
GB1578240A (en) Medicament pack and agent for the treatment of climacteric deficiency symptoms
Ricci et al. Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis
EP0662324A1 (en) Use of beta-adrenergic agonists for treating loss of function of striated muscles
JP2001516720A (ja) プロゲスチン/エストロゲンからなる第一相とプロゲスチンからなる第二相とを有する経口避妊薬製剤
US20240173334A1 (en) Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy
JP2000515889A (ja) プロゲスチンとエストロゲンとの混合剤からなる二相性避妊法およびキット
JP2927830B2 (ja) ダナゾール坐剤
CA2272891A1 (en) Method of preventing neurodegeneration and cognitive dysfunction using 17.alpha.-dihydroequilenin
WO1995005828A1 (de) PROGESTERONANTAGONISTISCH- UND ANTIÖSTROGEN WIRKSAME VERBINDUNGEN FÜR DIE BEHANDLUNG DES $i(LEIOMYOMATA UTERI)
WO1999051214A2 (en) Progestogen-only contraceptive kit
Crona et al. The effects of two gonane progestins alone and in combination with ethinyl estradiol on serum lipoproteins